Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: A prospective, multicenter, randomized, open-label study

Scandinavian Journal of Gastroenterology

Volumn 47, Issue 8-9, 2012, Pages 1048-1055

  Kim, Bo Hyun ^a,b   Lee, Youn Jae ^c   Kim, Won ^d   Yoon, Jung Hwan ^e   Jung, Eun Uk ^c   Park, Sung Jae ^c   Kim, Yoon Jun ^e   Lee, Hyo Suk ^e  

^a Bundang Jesaeng Hospital   (South Korea)

^b National Cancer Center   (South Korea)

^c Inje University College of Medicine   (South Korea)

^d Seoul National University Boramae Hospital   (South Korea)

^e Seoul National University College of Medicine   (South Korea)

Author keywords

Chronic hepatitis B; HBV DNA; Peginterferon 2a; Thymosin 1

Indexed keywords

ALANINE AMINOTRANSFERASE; DNA; HEPATITIS B(E) ANTIGEN; PEGINTERFERON ALPHA2A; THYMOSIN ALPHA1;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPEN STUDY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; TREATMENT DURATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; STATISTICS, NONPARAMETRIC; THYMOSIN; YOUNG ADULT;

EID: 84865778313     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2012.694902     Document Type: Article

References (32)

1. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-500.
2. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347: 168-74.
3. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130: 678-86.
4. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295: 65-73.
5. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10: 298-305.
6. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009;49: S103-11.
7. Sjogren MH. Thymalfasin: an immune system enhancer for the treatment of liver disease. J Gastroenterol Hepatol 2004; 19(Suppl 6): S69-72.
8. Janssen HLA, Van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365: 123-9.
9. Andreone P, Cursaro C, Gramenzi A, Zavagliz C, Rezakovic I, Altomare E, et al. A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment inpatients with hepatitis B e antigen antibody-and hepatitis B virus DNA-positive chronic hepatitis B. Hepatology 1996;24: 774-7.
10. Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology 1998;27: 1383-7.
11. Iino S, Toyota J, Kumada H, Kiyosawa K, Kakumu S, Sata M, et al. The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial. J Viral Hepat 2005;12: 300-6.
12. You J, Zhuang L, Cheng HY, Yan SM, Yu L, Huang JH, et al. Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study. World J Gastroenterol 2006;12: 6715-21.
13. You J, Zhuang L, Tang BZ, Yang WB, Ding SY, Li W, et al. A randomized controlled clinical trial on the treatment of Thymosin a1 versus interferon-alpha in patients with hepatitis B. World J Gastroenterol 2001;7: 411-14.
14. Zavaglia C, Severini R, Tinelli C, Franzone JS, Airoldi A, Tempini S, et al. A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B. Dig Dis Sci 2000;45: 690-6.
15. Yang YF, Zhao W, Zhong YD, Yang YJ, Shen L, Zhang N, et al. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis. Antiviral Res 2008;77: 136-41.
16. Saruc M, Ozden N, Turkel N, Ayhan S, Hock LM, Tuzcuoglu I, et al. Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B. J Pharm Sci 2003;92: 1386-95.
17. Mutchnick MG, Lindsay KL, Schiff ER, Cummings GD, Appelman HD, Peleman RR, et al. Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. J Viral Hepat 1999;6: 397-403.
18. De Roy PG. Helsinki and the Declaration of Helsinki. World Med J 2004;50: 9-11.
19. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001;357: 1191-4.
20. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352: 2682-95.
21. Casagrande JT, Pike MC. An improved approximate formula for calculating sample sizes for comparing two binomial distributions. Biometrics 1978;34: 483-6.
22. Chow S, Shao J, Wang H. Sample size calculations in clinical research 2003; Marcel Dekker Inc.; New York: NY, US.
23. Zhuang L, You J, Tang BZ, Ding SY, Yan KH, Peng D, et al. Preliminary results of Thymosin-a1 versus interferon-alpha-treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B. World J Gastroenterol 2001;7: 407-10.
24. Song BC, Cui XJ, Kim H. Hepatitis B virus genotypes in Korea: an endemic area of hepatitis B virus infection. Inter-virology 2005;48: 133-7.
25. Chien RN, Lin CY, Yeh CT, Liaw YF. Hepatitis B virus genotype B is associated with better response to thymosin alpha1 therapy than genotype C. J Viral Hepat 2006;13: 845-50.
26. Kim HS, Kim HJ, Shin WG, Kim KH, Lee JH, Kim HY, et al. Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2009;136: 505-12.
27. European Association For the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50: 227-42.
28. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegy-lated interferon alfa-2a in HBeAg-negative patients. Hepatol-ogy 2009;49: 1151-7.
29. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009;49: 1141-50.
30. Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008;47: 428-34.
31. Chan HL, Wong VW, Wong GL, Chim AM, Chan HY, Sung JJ. Early hepatitis B virus DNA suppression can predict virologic response to peginterferon and lamivudine treatment. Clin Gastroenterol Hepatol 2008;6: 1022-6.
32. Lok AS-F. Navigating the maze of hepatitis B treatments. Gastroenterology 2007;132: 1586-94.